ABCG2 and rheumatoid arthritis: In a 12-month open, prospective trial enrolling 106 RA patients, the combination of a BCRP inhibitor cyclosporine and leflunomide provided statistically significant benefit (77), suggesting that BCRP inhibition could be a potential approach for improving the nonresponse to leflunomide.